403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Anavex Life Sciences Stock Rises After Experimental Alzheimer's Drug Slows Cognitive Decline In Study
(MENAFN- AsiaNet News)
Anavex Life Sciences Corp. (AVXL) on Tuesday announced that its experimental Alzheimer's drug demonstrated cognitive stabilization in patients with early Alzheimer's disease.
After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, comparable to the minimal decline in pre-dementia ageing adults.
Shares of the company rose 4% in the pre-market session.
Get updates to this developing story <directly on Stocktwits.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment